Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432670 | 0.85 | NPC1 (0.59) | L3MBTL1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL29405082 | 0.85 | NPC1 (0.59) | L3MBTL1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL6795231 | 0.83 | ALDH1A1 (0.66) | L3MBTL1NPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL9656225 | 0.82 | DAO (0.55) | L3MBTL1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL8362996 | 0.82 | NPC1 (0.56) | L3MBTL1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL4635750 | 0.82 | RAB9A (0.53) | L3MBTL1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL1457922 | 0.82 | NPC1 (0.53) | L3MBTL1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL11163593 | 0.82 | NPC1 (0.58) | L3MBTL1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3387605 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2E1 | |
| Hydrochloric Acid SCHEMBL11174365 | 0.81 | NPC1 (0.57) | L3MBTL1NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4003906-A | Substituted pyridinyl methylthio or (methylsulfonyl)benzeneamines | THE DOW CHEMICAL COMPANY (US) | 1977-01-18 | — | — | US | claimed |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2207547-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009045700-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045700-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-0335144-A1 | 3,4,5-Substituted-4H-1,2,4-triazoles, their preparation and their use | BOEHRINGER INGELHEIM KG (DE) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | L3MBTL1 888/4885NPC1 3726/4885RAB9A 3493/4885 |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | L3MBTL1 888/4885NPC1 3726/4885RAB9A 3493/4885 |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | L3MBTL1 2184/4885NPC1 2059/4885RAB9A 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.